TY - JOUR
AB - ABSTRACT 71 Antiviral Therapy 2001; 6: S71 Accelerating AIDS vaccine development: IAVI scientific agenda WC Koff International AIDS Vaccine Initiative, New York, NY, USA Since the beginning of the AIDS pandemic, nearly 60 million persons have become infected with HIV, with over 95% of new infections occurring in the devel- oping world, over 20 million persons have died from AIDS, more than 13 million children have been orphaned due to HIV/AIDS, and HIV continues its relentless global spread virtually unchecked. As a result, development of safe and effective HIV vaccines for the prevention of AIDS has become an interna- tional public health priority. IAVI, a non-governmental organization, founded in 1996, is focused on a mission to ensure that AIDS vaccines are successfully devel- oped, licensed and made available to populations in need throughout the world. IAVI’s scientific agenda is targetted at identifying promising new strategies for AIDS vaccines, developing these candidates for clinical trials, prioritizing the vaccines in Phase I/II clinical trials and non-human primate studies, and accelerating the most promising candidates into Phase III efficacy trials in the developing world. IAVI works as a virtual vaccine company, bringing industrial project manage- ment and vaccine development skills to the 
TI - Abstracts: 
JF - Antiviral Therapy
DO - 10.1177/135965350100600209
DA - 2000-02-01
UR - https://www.deepdyve.com/lp/sage/abstracts-LcueBLr2ML
SP - 71
EP - 142
VL - 6
IS - 2
DP - DeepDyve
ER -